LONDON – Amiko Digital Health Limited, a company that develops advanced medication sensor technologies and artificial intelligence-powered digital health tools, has received CE Mark for use of the Respiro platform with Teva’s Spiromax inhaler, Chiesi’s Nexthaler inhaler and GlaxoSmithKline’s Ellipta inhaler. “Receiving the CE Mark is a significant milestone toward the global commercialization of our connected inhaler technology,” said Federica Iovine, director of regulatory affairs at Amiko, in a statement. Respiro offers advanced inhaler sensors and connected health tools, enabling real-time monitoring of medication use and patient health. Combined with inhalers for asthma, chronic obstructive pulmonary disease and cystic fibrosis, the sensors automatically capture data on the patient’s inhalation profiles to monitor when and how well patients use their medication.
You are here: / / Amiko’s Respiro platform receives CE Mark